SG11201907742YA - Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof - Google Patents

Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof

Info

Publication number
SG11201907742YA
SG11201907742YA SG11201907742YA SG11201907742YA SG11201907742YA SG 11201907742Y A SG11201907742Y A SG 11201907742YA SG 11201907742Y A SG11201907742Y A SG 11201907742YA SG 11201907742Y A SG11201907742Y A SG 11201907742YA SG 11201907742Y A SG11201907742Y A SG 11201907742YA
Authority
SG
Singapore
Prior art keywords
international
new york
pharmaceutical compositions
pct
microbiome
Prior art date
Application number
SG11201907742YA
Inventor
Gary D Wu
Hongzhe Lee
Farah Babakhani
Luciano Adorini
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of SG11201907742YA publication Critical patent/SG11201907742YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIPO I PCT oimiolo °nolo °nom om (10) International Publication Number WO 2018/156916 A3 (51) International Patent Classification: A61K 31/575 (2006.01) A61K 35/00 (2006.01) A61K 31/00 (2006.01) A61K 35/74 (2015.01) A61K 31/56 (2006.01) (21) International Application Number: PCT/US2018/019451 (22) International Filing Date: 23 February 2018 (23.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/462,658 23 February 2017 (23.02.2017) US (71) Applicant: INTERCEPT PHARMACEUTICALS, INC [US/US]; 10 Hudson Yards, 37th Floor, New York, New York 10001 (US). (72) Inventors: WU, Gary D.; 28 Whitemarsh Road, Ard- more, Pennsylvania 1903 (US). LEE, Hongzhe; 110 Fairview Road, Penn Valley, Pennsylvania 19072 (US). BABAKHANI, Farah; 12334 Darkwood Rd, San Diego, California 92129 (US). ADORINI, Luciano; via Bronzino 8, 20133 Milano (IT). (74) Agent: IWAMOTO-FAN, Michelle; 10 Hudson Yards, 37th Floor, New York, New York 10001 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: PHARMACEUTICAL COMPOSITIONS OF A BILE ACID DERIVATIVE AND MICROBIOME AND USES THEREOF Figure 1 16 44 10 Dasy OCA dot& M 5 1025 0 (57) : The application relates to pharmaceutical compositions comprising a compound of formula I and one or more gut \" microbiome species, and methods of preparing and using the same. [Continued on next page] WO 2018/156916 A3 MIDEDIMOMOIDIONDEIDIOMOHEROIHOIROMOMI00# Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the international search report: 11 October 2018 (11.10.2018)
SG11201907742YA 2017-02-23 2018-02-23 Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof SG11201907742YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762462658P 2017-02-23 2017-02-23
PCT/US2018/019451 WO2018156916A2 (en) 2017-02-23 2018-02-23 Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof

Publications (1)

Publication Number Publication Date
SG11201907742YA true SG11201907742YA (en) 2019-09-27

Family

ID=63254469

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907742YA SG11201907742YA (en) 2017-02-23 2018-02-23 Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof

Country Status (12)

Country Link
US (1) US20200164005A1 (en)
EP (1) EP3585405A4 (en)
JP (1) JP2020509001A (en)
KR (1) KR20190117687A (en)
CN (1) CN110461337A (en)
AU (1) AU2018225255A1 (en)
BR (1) BR112019017417A2 (en)
CA (1) CA3053935A1 (en)
IL (1) IL268760A (en)
MX (1) MX2019009861A (en)
SG (1) SG11201907742YA (en)
WO (1) WO2018156916A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136269A1 (en) * 2018-01-05 2019-07-11 Nubiyota Llc Compositions comprising co-selected microbiota and methods for use thereof
US20220023355A1 (en) * 2019-02-04 2022-01-27 Riken Pharmaceutical composition for prevention, amelioration, or treatment of skin disease
US20220096495A1 (en) * 2019-02-04 2022-03-31 Intercept Pharmaceuticals, Inc. Treatment and prevention of intestinal inflammatory diseases with a bile acid derivative
US20220193151A1 (en) * 2019-03-26 2022-06-23 The Children's Medical Center Corporation Therapeutic microbiota for the treatment and/or prevention of dysbiosis
CN109852604A (en) * 2019-03-28 2019-06-07 贵州大学 The preparation method and application of the net unit cell category bacteria immobilization bacterium of efficient degradation sclerotium
CN114245743B (en) * 2019-07-30 2023-12-08 Ko生物技术有限公司 Compositions and methods for preventing, alleviating or treating liver injury
CN112980712A (en) * 2019-12-14 2021-06-18 山东大学 Microbial composition for regulating emotion and intestinal flora stability of plateau population and application thereof
WO2021137494A1 (en) * 2020-01-02 2021-07-08 삼육대학교산학협력단 Composition for preventing or treating diabetes comprising butyricimonas sp. strain as active ingredient
CN113213984B (en) * 2020-01-21 2022-09-09 吉林农业大学 Biological organic fertilizer containing bacillus vallismortis and preparation method and application thereof
CN111254207A (en) * 2020-01-22 2020-06-09 郑州大学第一附属医院 Intestinal microbial marker for distinguishing autoimmune hepatitis from healthy people and application thereof
CN111117935A (en) * 2020-02-10 2020-05-08 农业农村部食物与营养发展研究所 Microbial agent for inhibiting muscle synthesis and application thereof
CN111686134A (en) * 2020-05-15 2020-09-22 上海市第六人民医院东院 Probiotic composition and preparation method and application thereof
US20230233620A1 (en) * 2020-05-21 2023-07-27 Chan Zuckerberg Biohub, Inc. High-complexity synthetic gut bacterial communities
EP4188110A1 (en) * 2020-07-30 2023-06-07 Bactana Corp. Methods and compositions for treating metabolic conditions
KR102269966B1 (en) 2021-01-12 2021-06-28 주식회사 바이오뱅크힐링 Ruminococcus faecis strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof
CN113186132B (en) * 2021-05-07 2023-05-23 广东丽豪生物农业有限公司 Microbial agent suitable for corn planting and application
WO2022271729A1 (en) * 2021-06-21 2022-12-29 Pendulum Therapeutics, Inc. Compositions comprising microbes and methods of use and making thereof
CN114028938B (en) * 2021-10-13 2024-03-22 华中农业大学 Screening and application of high-temperature-resistant ammonia-removing bacteria
CN113789289B (en) * 2021-11-05 2023-05-16 中山大学附属第三医院粤东医院 Intestinal microorganism combination for evaluating systemic lupus erythematosus disease risk and detection reagent thereof
CN113881609B (en) * 2021-11-23 2022-12-23 山东省花生研究所 Acinetobacter pitteus YY-7S and application thereof
CN114410554B (en) * 2022-03-29 2022-06-14 广东省科学院生态环境与土壤研究所 Chitin-phagocytic bacterium with aerobic arsenic methylation and volatilization functions and application thereof
WO2024005587A1 (en) * 2022-06-30 2024-01-04 일동제약(주) Novel use of isoxazole derivative or salt thereof
CN115161406B (en) * 2022-07-18 2023-04-21 中国农业科学院特产研究所 Construction method of synthetic flora and application of synthetic flora in high-quality cultivation of medicinal plants
CN115747111B (en) * 2022-11-25 2023-12-12 四川大学 Pediococcus pentosaceus and application thereof
CN115976122A (en) * 2023-01-10 2023-04-18 四川轻化工大学 Binary mixed bacteria ester-producing fermentation system and method for producing esterified liquid by using same and application of system
CN116694535A (en) * 2023-07-20 2023-09-05 四川大学 Lactobacillus pentosus W19 and application thereof
CN117797176A (en) * 2024-03-01 2024-04-02 南京大学 Application of clostridium bifidum in preparation of medicine for treating non-alcoholic fatty liver disease and medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA118673C2 (en) * 2013-05-14 2019-02-25 Інтерсепт Фармасутікалз, Інк. 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
US20150258052A1 (en) * 2014-03-13 2015-09-17 Salk Institute For Biological Studies Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
US20160095339A1 (en) * 2014-10-01 2016-04-07 Mead Johnson Nutrition Company Nutritional composition for gastrointestinal environment to provide improved microbiome and metabolic profile
CN106083978A (en) * 2015-04-28 2016-11-09 上海迪诺医药科技有限公司 Sulfonyl amino carbonyl derivant, its pharmaceutical composition and application

Also Published As

Publication number Publication date
AU2018225255A1 (en) 2019-09-05
MX2019009861A (en) 2020-07-14
KR20190117687A (en) 2019-10-16
WO2018156916A3 (en) 2018-10-11
IL268760A (en) 2019-10-31
EP3585405A4 (en) 2020-12-09
CA3053935A1 (en) 2018-08-30
WO2018156916A2 (en) 2018-08-30
CN110461337A (en) 2019-11-15
JP2020509001A (en) 2020-03-26
US20200164005A1 (en) 2020-05-28
EP3585405A2 (en) 2020-01-01
BR112019017417A2 (en) 2020-04-07

Similar Documents

Publication Publication Date Title
SG11201907742YA (en) Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof
SG11201906412SA (en) Pyridine compounds as allosteric shp2 inhibitors
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201901006RA (en) Systems and methods for enhanced organizational transparency using a credit chain
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201909918XA (en) Compositions and methods for improving sample identification in indexed nucleic acid libraries
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201804384UA (en) Geometric configurations for gastric residence systems
SG11201809751XA (en) Egfr inhibitor compounds
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201906163TA (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201804721SA (en) Modulators of complement activity
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201906222WA (en) Jak1 selective inhibitors
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201804587QA (en) Isoindole compounds
SG11201906139VA (en) Compositions and methods related to engineered fc constructs
SG11201809882XA (en) Pharmaceutical combinations for treating cancer